Visterra Revenue and Competitors

Visterra discovers and develops novel drugs utilizing its proprietary platform based on the atomic interaction network analyses of proteins. The company's innovative technology platform enables a more in depth, three-dimensional structural understanding of proteins to (i) identify unique target epitopes and (ii) guide the design of novel drugs to effectively combat disease. The company has established proof-of-concept with its lead product candidate, VIS410, a monoclonal antibody which represents a significant advancement in the treatment and prevention of both seasonal and pandemic influenza. VIS410 is also an important validation of the broad potential of Visterra's technology platform. The company is building a proprietary pipeline of novel drugs targeting infectious diseases. Through a coalition of partners with a shared mission – including U.S. and non-U.S. governments, global foundations and pharmaceutical companies – Visterra is committed to providing safe and effective therapies to patients in both the developed and developing world.